Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May;473:1–14. doi: 10.1016/j.ydbio.2021.01.002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 5 — VEGFA signalling is required for both venous and arterial enhancer activity. A-B. Representative 24 hpf venous tg(Ephb4-2:GFP) (A) and arterial/angiogenic tg(Dll4in3:GFP) (B) zebrafish embryos treated with either DMSO control or different concentrations of VEGFR inhibitor SU5416. Red bracket indicates dorsal aorta, white bracket indicates cardinal vein. C. Graph depicting observed GFP expression levels in transgenic embryos treated with DMSO control or different levels of SU5416. Ephb4-2:GFP cnt n = 26, 0.63 μM SU5416 n = 27, 1.25 μM SU5416 n = 72, 2.5 μM SU5416 n = 62, 5 μM SU5416 n = 72. Dll4in3:GFP cnt n = 32, 0.63 μM SU5416 n = 29, 1.25 μM SU5416 n = 31, 2.5 μM SU5416 n = 26, 5 μM SU5416 n = 33.